Zusammenfassung
Die Chemotherapie mit zytotoxischen Substanzen ist heute das zentrale medikamentöse Behandlungsprinzip in der Kinderonkologie. Die Arzneistoffe werden mit hoher Dosisintensität in Kombinationsregimen eingesetzt, die in sequenziellen randomisierten Therapieoptimierungsstudien entwickelt wurden. Patienten mit lokalisierten soliden Tumoren werden zusätzlich zur Lokaltherapie adjuvant mit Chemotherapie behandelt, um Rezidive durch klinisch nicht manifeste Metastasen zu verhindern. Grundkenntnisse der klinischen Pharmakologie der verwendeten Zytostatika sind eine wesentliche Voraussetzung für die sichere und wirksame Anwendung durch den pädiatrischen Onkologen und Gegenstand dieses Kapitels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bernini JC, Fort DW, Griener JC, et al. (1995) Aminophylline for methotrexate-induced neurotoxicity. Lancet 345: 544–547
Berthold F, Boos J, Burdach S, et al. (2005) Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncology 6: 649–658
Burdach S, Jurgens H, Peters C, et al. (1993) Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewings-Sarcoma. J Clin Oncol 11: 1482–1488
Browder T, Butterfield CE, Kraling BM, et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878–1886
Creutzig U, Zimmermann M, Bourquin JP, et al. (2013) Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 122: 37–43
Frei E, 3rd, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585–594
Furman WL, Crews KR, Billups C, et al. (2006) Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24: 563–570
George P, Hernandez K, Hustu O, et al. (1968) A study of »total therapy« of acute lymphocytic leukemia in children. J Pediatr 72: 399–408
Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643–3653
Grohar PJ, Segars LE, Yeung C, et al. (2014) Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res 20: 1064–1066
Krause AS, Weihrauch MR, Bode U, et al. (2002) Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 43: 2139–2143
Kushner BH, Cheung NKV, Kramer K, et al. (1998) Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 16: 3880–3889
Ladenstein R, Lasset C, Hartmann O, et al. (1993) Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11: 2330–2341
Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225–229
Link MP, Goorin AM, Miser AW, et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600–1606
Lipshultz SE, Lipsitz SR, Mone SM, et al. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332: 1738–1743
Newell DR, Pearson AD, Balmanno K, et al. (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children’s Cancer Study Group. J Clin Oncol 11: 2314–2323
Pelgrims J, De Vos F, Van den Brande J, et al. (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82: 291–294
Relling MV, Hancock ML, Boyett JM, et al. (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93: 2817–2823
Riehm H, Gadner H, Welte K (1977) The west-berlin therapy study of acute lymphoblastic leukemia in childhood – report after 6 years. Klin Padiatr 189: 89–102
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Rössig, C., Langebrake, C., Burdach, S. (2018). Medikamentöse Therapie. In: Niemeyer, C., Eggert, A. (eds) Pädiatrische Hämatologie und Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43686-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-43686-8_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43685-1
Online ISBN: 978-3-662-43686-8
eBook Packages: Medicine (German Language)